Kevin Miller, MD
Cardiovascular Disease · Edgewood, KYNPI 1467445148
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,848 of the $9,525 with a category attached, or 82.4%. 27 manufacturers reported payments, led by Medtronic at 30.1% of the total. Reporting peaked in 2022 at $3,428 and has fallen 71.7% since, to $971 in 2025.
Across 345 payments — averaging $27.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Amgen$1K
- Davol Inc.$1K
- Novartis$871
- Johnson & Johnson$390
- Abiomed$334
- plus $3K from 21 others
What the payments were for
- Travel & lodging$1,66217%
- Food & beverage$7,84882%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 25 | $2,869 |
| Amgen | 139 | $1,459 |
| Davol Inc. | 10 | $1,087 |
| Novartis | 62 | $871 |
| Johnson & Johnson(2 entities) | 25 | $390 |
| Abiomed | 6 | $334 |
| Medical Device Business Services, Inc. | 5 | $331 |
| Boehringer Ingelheim | 18 | $325 |
| Boston Scientific | 5 | $310 |
| E.r. Squibb & Sons, L.L.C. | 13 | $271 |
| Abbott | 3 | $221 |
| AstraZeneca | 3 | $181 |
| Pfizer | 4 | $137 |
| Genentech USA, Inc. | 1 | $126 |
| Siemens Medical Solutions USA, Inc. | 3 | $106 |
| Edwards Lifesciences | 2 | $85 |
| Sanofi-aventis U.S. LLC | 3 | $84 |
| Biosense Webster, Inc. | 3 | $66 |
| Cardiva Medical, Inc. | 3 | $59 |
| Amarin Pharma, Inc. | 3 | $50 |
| Merck | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Acist Medical Systems, Inc. | 1 | $33 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Organogenesis Inc. | 1 | $16 |
| W. L. Gore & Associates, Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PHASIX$657
- COREVALVE EVOLUT R$346
- LINX Reflux Management System$280
- RESOLUTE ONYX$232
- WATCHMAN Access System$131
- FFRangio$123
- AVVIGO Guidance System$121
- ELIQUIS$118
- VYNDAQEL$116
- Xience Sierra Coronary Stent$115
- ONYX FRONTIER$112
- XenMatrix Surgical Graft$104
- Evera$100
How this compares
$9,525 in reported general payments places this provider in the 85th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 537 | $510,114 |
| Repatha SureclickEvolocumab | 329 | $302,127 |
| EntrestoSacubitril/Valsartan | 154 | $164,055 |
| XareltoRivaroxaban | 94 | $90,519 |
| Praluent PenAlirocumab | 100 | $77,333 |
| JardianceEmpagliflozin | 54 | $63,118 |
| FarxigaDapagliflozin Propanediol | 62 | $60,686 |
| Repatha SyringeEvolocumab | 25 | $22,408 |
| Repatha PushtronexEvolocumab | 23 | $18,800 |
| Metoprolol Succinate | 974 | $11,775 |
| Rosuvastatin Calcium | 645 | $6,218 |
| Atorvastatin Calcium | 707 | $5,303 |
| Nebivolol Hcl | 111 | $5,244 |
| BrilintaTicagrelor | 11 | $4,769 |
| Ezetimibe | 238 | $4,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $137 | $510,114537 claims |
| NovartisEntresto | $871 | $164,055154 claims |
| Johnson & JohnsonXarelto | $390 | $90,51994 claims |
| AstraZenecaFarxiga, Brilinta | $181 | $65,45473 claims |
| Boehringer IngelheimJardiance | $325 | $63,11854 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Edgewood
- Stephen SchutzmanEdgewood$17K
- Darryl DiasEdgewood$7K
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- William SkinnerLexington$312K
- Prabodh MehtaElizabethtown$133K
- John HarrisLouisville$129K
- David MoliternoLexington$115K
- Rohan SamsonLouisville$94K
- Srinivasa AppakonduHazard$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.